Comparative Effectiveness of Ezetimibe in Improving Lipid Profile in Non-Alcoholic Fatty Liver Disease Patients: Statins Still Rule

• DOI: 10.5539/ijb.v4n2p184
• Publication Date: 2012-03-31T01:10:10Z
• Authors: Mohammad Ebrahim ...; Mohsen Amini; Hossein Khedmat; Fatemeh Daraei; Reza Mohtashami; Ashraf Karbasi; Saeed Taheri
• Keywords: Ezetimibe; Gemfibrozil; Hyperlipidemia; Lipid Profile

Introduction: Dyslipidemias are well-documented disorders in nonalcoholic fatty liver disease (NAFLD) patients; and have been implicated as an etiology prognosis factor for the disease, well. In current study, we aimed to evaluate impact of various antihyperlipidemic regimens on serum cholesterol levels. Method material: A longitudinally study was conducted 98 NAFLD patients were consecutively entered into analysis. Five types used: Ezetimibe alone (10mg/day; 3 patients); (10mg/day) plus gemfibrozil (600mg/day) (28 Gemfibrozil (600mg/day; 26 Atorvastatin (20mg/day; 15 Simvastatin patients). Results: followed 138±83 days after drugs administered. Serum total levels experiences highest fall by atorvastatin therapy (p=0.006). LDL also decreased most significantly through with or simvastatin (p<0.001). There no difference between drug modifying HDL, triglyceride, AST ALT (p>0.1 all). Conclusion: cannot improve hyperlipidemias patients, while statins, especially is highly potent this purpose; recommended hyperlipidemic patients. For who unfavorable reactions statins subjected use ezetimibe, recommend its co-administration gemfibrozil. Future studies randomized blind approaches needed.